NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

NRx Pharmaceuticals (NRXP) announced receipt of clearance from the FDA to initiate a clinical trial of NRX-101 vs. placebo in patients with depression and suicidality who are being treated with either Robotic-assisted Transcranial Magnetic Stimulation or sham TMS. The placebo-controlled phase 2/3 trial is identified as A Randomized, Double-Blind, Three-Arm Study of NRX-101 as Adjunctive Therapy to Active or Sham Transcranial Magnetic Stimulation in Adults with Treatment Resistant Major Depressive Disorder.